• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of lncRNA AK023948 on rats with postmenopausal osteoporosis via PI3K/AKT signaling pathway.
CONCLUSIONS: LncRNA AK0 can regulate the phosphorylation level of AKT in osteoblasts of rats with estrogen deficiency-related osteoporosis through the PI3K/AKT signaling pathway, thus regulating the proliferation of osteoblasts. It is speculated that lncRNA AK0 may be an important factor in regulating the PI3K/AKT signaling pathway. PMID: 32196569 [PubMed - as supplied by publisher]
Source: European Review for Medical and Pharmacological Sciences - March 21, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

LncRNA UCA1 affects osteoblast proliferation and differentiation by regulating BMP-2 expression.
CONCLUSIONS: Inhibiting lncRNA UCA1 can promote the proliferation and differentiation of osteoblasts by activating the BMP-2/(Smad1/5/8) signaling pathway in osteoblasts. Therefore, UCA1 is expected to be a new therapeutic target for OST. PMID: 31486475 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - September 7, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

LncRNA MALAT1 inhibits osteogenic differentiation of mesenchymal stem cells in osteoporosis rats through MAPK signaling pathway.
CONCLUSIONS: LncRNA MALAT1 was lowly expressed in OP rats. Moreover, it inhibited osteogenic differentiation of BMSCs by enhancing the activation of the MAPK signaling pathway, thereby promoting OP progression. PMID: 31210287 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 20, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

CRNDE impacts the proliferation of osteoclast by estrogen deficiency in postmenopausal osteoporosis.
CONCLUSIONS: We found that lncRNA CRNDE was closely related to the postmenopausal osteoporosis with estrogen deficiency. CRNDE may be involved in the development and progression of postmenopausal osteoporosis in the absence of estrogen and become a potential target for treating. PMID: 30280760 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 5, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research